A composition for VAA-mediated administration of a therapeutic product having a controlled transgenic expression ablation system, said composition comprising (a) a VAA vector containing a nucleic acid molecule comprising: (i) a nucleic acid sequence encoding a therapeutic product operably linked to a promoter that controls transcription； and (ii) at least one endonuclease ablation site comprising a nucleic acid sequence of at least one base pair specifically recognized by at least ten (10X) zinc fingers, said at least one endonuclease ablation site being located at less in 5 'position with respect to the sequence encoding the therapeutic product； (b) at least one ablator containing a chimeric endonuclease comprising at least ten copies of a zinc finger domain, linked to a functional endonuclease catalytic domain in operative association with a promoter, in which the transcription activity and / or ablation is induced in response to a pharmacological agent, said domain recognizing at least ten (10X) zinc fingers specifically said sequence of at least 30 base pairs of (a) (ii) at said at least one ablation site of endonuclease and comprising at least 10 recognition helices.Una composición para la administración mediada por VAA de un producto terapéutico que tiene un sistema de ablación de expresión transgénica controlada, comprendiendo dicha composición (a) un vector VAA que contiene una molécula de ácido nucleico que comprende: (i) una secuencia de ácido nucleico que codifica un producto terapéutico unido operativamente a un promotor que controla la transcripción； y (ii) al menos un sitio de ablación de endonucleasa que comprende una secuencia de ácido nucleico de al menos de pares de bases reconocida específicamente por al menos diez (10X) dedos de cinc, localizándose dicho al menos un sitio de ablación de endonucleasa al menos en posición 5' con respecto a la secuencia que codifica el producto terapéutico； (b) al menos un ablacionador que comprende una endonucleasa
